Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. (Nasdaq: NAUT) is a proteomics company that completed its public debut in June 2021 through a merger with ARYA Sciences Acquisition Corp III, a blank-check vehicle sponsored by Perceptive Advisors. The company is developing a single-molecule protein analysis platform targeting applications in drug discovery, diagnostics, and life sciences research broadly. As a post-merger public entity, Nautilus continues to file periodic disclosures with the SEC, including the Form 8-K submitted on June 18, 2026, bearing accession number 0001808805-26-000027. To access the full filing history, deal structure, and real-time tracking data on NAUT and hundreds of other de-SPAC companies, sign up for a SpacDesk account today.